While its customer are shedding pounds, Novo Nordisk, creator of the mega-hit drug Ozempic, is shedding loads of market value amid collapsing sales.

One year ago, the Danish pharmaceutical giant's market cap exceeded the size of its entire home country's economy. But this week, it's continued its steady but drastic decline — which saw its CEO get the axe — by losing nearly $100 billion in value after slashing its sales forecast for the second time this year. Following the first revision, growth was expected to be between 13 and 21 percent, but it's now down to between eight and 14 percent. Its share price dropped by 30 percent following the twice-updated forecast, making it its worst week in more than twenty years, The Guardian reported.

Novo Nordisk's flagship product is semaglutide. So

See Full Page